OBJECTIVES: To evaluate the determinants of HIV-1 RNA shedding in cervicovaginal secretions and the effects of antiretroviral therapy in a group of infected women. METHODS: A total of 122 women from whom paired peripheral blood and cervicovaginal lavage samples were available were enrolled in the study. HIV-1 RNA was quantified in the plasma and cell-free fraction of cervicovaginal lavages by the nucleic acid sequence-based amplification assay (lower limit of detection 80 copies/ml). RESULTS: Seventy-one per cent of the women had detectable viral load in the cervicovaginal lavage and this appeared to be correlated to plasma viral load and to the degree of immunodeficiency as expressed by the absolute number of CD4 cells. Antiretroviral-treated patients had a lower risk of shedding the virus in the genital tract, but this association was limited to patients treated with highly active antiretroviral therapy (HAART). However, in 25% of women with undetectable plasma viral load, a genital shedding of the virus was demonstrated. CONCLUSION: Plasma viral load may fail as a marker of infectivity of genital secretions. HAART treatment seems to be more efficacious in suppressing viral shedding at the genital level. The female genital tract represents a distinct compartment for HIV-1 replication/evolution.
OBJECTIVES: To evaluate the determinants of HIV-1 RNA shedding in cervicovaginal secretions and the effects of antiretroviral therapy in a group of infected women. METHODS: A total of 122 women from whom paired peripheral blood and cervicovaginal lavage samples were available were enrolled in the study. HIV-1 RNA was quantified in the plasma and cell-free fraction of cervicovaginal lavages by the nucleic acid sequence-based amplification assay (lower limit of detection 80 copies/ml). RESULTS: Seventy-one per cent of the women had detectable viral load in the cervicovaginal lavage and this appeared to be correlated to plasma viral load and to the degree of immunodeficiency as expressed by the absolute number of CD4 cells. Antiretroviral-treated patients had a lower risk of shedding the virus in the genital tract, but this association was limited to patients treated with highly active antiretroviral therapy (HAART). However, in 25% of women with undetectable plasma viral load, a genital shedding of the virus was demonstrated. CONCLUSION: Plasma viral load may fail as a marker of infectivity of genital secretions. HAART treatment seems to be more efficacious in suppressing viral shedding at the genital level. The female genital tract represents a distinct compartment for HIV-1 replication/evolution.
Authors: Cécile L Tremblay; Jean-Guy Baril; David Fletcher; Donald Kilby; Paul Macpherson; Stephen D Shafran; Mark W Tyndall Journal: Can J Infect Dis Med Microbiol Date: 2010-08 Impact factor: 2.471
Authors: Sharon A Greene; Christine J McGrath; Dara A Lehman; Kara G Marson; T Tony Trinh; Nelly Yatich; Evans Nyongesa-Malava; Catherine Kiptinness; Barbra A Richardson; Grace C John-Stewart; Hugo De Vuyst; Samah R Sakr; Nelly R Mugo; Michael H Chung Journal: Clin Infect Dis Date: 2018-05-17 Impact factor: 9.079
Authors: Marta Bull; Caroline Mitchell; Jaime Soria; Sheila Styrchak; Corey Williams; Joan Dragavon; Kevin J Ryan; Edward Acosta; Frankline Onchiri; Robert W Coombs; Alberto La Rosa; Eduardo Ticona; Lisa M Frenkel Journal: J Infect Dis Date: 2020-08-04 Impact factor: 5.226
Authors: Pamela P Gumbi; Nonhlanhla N Nkwanyana; Alfred Bere; Wendy A Burgers; Clive M Gray; Anna-Lise Williamson; Margaret Hoffman; David Coetzee; Lynette Denny; Jo-Ann S Passmore Journal: J Virol Date: 2008-06-18 Impact factor: 5.103
Authors: Megan Justine Huchko; Victoria Woo; Teri Liegler; Anna Leddy; Karen Smith-McCune; George F Sawaya; Elizabeth A Bukusi; Craig R Cohen Journal: J Low Genit Tract Dis Date: 2013-07 Impact factor: 1.925
Authors: Victoria G Woo; Teri Liegler; Craig R Cohen; George F Sawaya; Karen Smith-McCune; Elizabeth A Bukusi; Megan J Huchko Journal: AIDS Res Hum Retroviruses Date: 2013-05-15 Impact factor: 2.205